ENDOSTATIN

Lung Cancer

Shanghai Chest Hospitalprotein_peptidePhase 4 / ApprovedDormant

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 57/ 100
Competitive Position: 65/ 100

Competitive context

299 Active assets in the Lung Cancer cohort.

Asset / Sponsor	Phase	Rating
CIS-DIAMMINEDICHLOROPLATINUM II University of Vermont	Phase 4	BB
Carboplatin SystImmune Inc.	Phase 4	BB
Desflurane Peter MacCallum Cancer Centre, Australia	Phase 4	BB
ETOPOSIDE SystImmune Inc.	Phase 3	BB
Nivolumab University of Chicago	Phase 4	BB

View all 50 →

Same molecule, other indications

ENDOSTATIN is also rated in:

non-small cell lung carcinomaActive

BB

Indicative · Phase 4

70 / 100

colorectal neoplasmActive

B

Indicative · Phase 3

63 / 100

lung neoplasmActive

B

Indicative · Phase 3

59 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.